^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PLK1 overexpression

i
Other names: PLK1, Polo Like Kinase 1, Serine/Threonine-Protein Kinase PLK1, Serine/Threonine-Protein Kinase 13, Polo-Like Kinase 1, STPK13, PLK-1, Cell Cycle Regulated Protein Kinase, Polo-Like Kinase (Drosophila), Polo (Drosophia)-Like Kinase
Entrez ID:
Related biomarkers:
4ms
PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer. (PubMed, Front Oncol)
In vitro studies were conducted using the PLK1 inhibitor volasertib and the PARP inhibitor olaparib, either alone or in combination, in PTC cell lines. Moreover, our findings indicate that inhibition of PLK1 can reinstate sensitivity in PARP inhibitor (PARPi) resistant TNBC cell lines. Our results shed light on the role of PLK1 in the pathogenesis and prognosis of Middle Eastern BC and support the potential clinical development of combined inhibition of PLK1 and PARP, a strategy that could potentially broaden the use of PLK1 and PARP inhibitors beyond BC cases lacking BRCA.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA (Breast cancer early onset) • PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression • BRCA mutation
|
Lynparza (olaparib) • volasertib (NBL-001)
4ms
Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with PLK1 Variant rs27770A>G. (PubMed, Cancers (Basel))
Bioinformatics analysis suggested that rs27770 A>G affects PLK1 mRNA secondary structure and alters the hsa-miR-100-5p/PLK1 interaction by forming an additional seedless binding site. This racial variation caused PLK1 to be more vulnerable to hsa-miR-100-5p inhibition, resulting in hsa-miR-100-5p being more favorable for HCC prognosis in the Asian population.
Journal
|
PLK1 (Polo Like Kinase 1) • MIR100 (MicroRNA 100)
|
PLK1 overexpression
6ms
The expression and clinical significance of PLK1/p-PLK1 protein in NK/T cell Lymphoma. (PubMed, Diagn Pathol)
The expression levels and active phosphorylation levels of PLK1 were significantly increased in NK/T cell lymphoma, and patients with overexpression of PLK1 and p-PLK1 had a poorer prognosis.
Journal
|
B2M (Beta-2-microglobulin) • PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
6ms
PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. (PubMed, Endocr Connect)
The efficacy of Rigosertib (RGS), targeting RAS/PI3K, CDKs and PLKs, and Poloxin (Pol), specifically targeting the PLK1 polo-box domain, was tested in TP53-mutated NCI-H295R, MUC-1, and CU-ACC2 cells and in TP53-wild-type CU-ACC1...TP53-mutated ACC cell lines demonstrated better response to PLK1i than wild-type CU-ACC1. These data suggest PLK1i may be a promising targeted treatment of a subset of ACC patients, pre-selected according to tumour genetic signature.
Journal
|
MUC1 (Mucin 1) • ACACA (Acetyl-CoA Carboxylase Alpha) • ACACB (Acetyl-CoA Carboxylase Beta)
|
TP53 mutation • TP53 wild-type • PLK1 overexpression • TP53 expression
|
Estybon (rigosertib)
6ms
Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer. (PubMed, Cell Rep)
We further show that high PLK1-expressing human breast tumors display gene expression patterns associated with SASP, NF-κβ signaling, and immune suppression. These findings underscore the need to understand the immune landscape in CIN tumors to identify more effective therapies, potentially combining immune checkpoint or NF-κβ inhibitors with current treatments.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PLK1 (Polo Like Kinase 1) • MRC1 (Mannose Receptor C-Type 1)
|
HER-2 overexpression • PLK1 overexpression
7ms
EGFR-mediated hyperacetylation of tubulin induced docetaxel resistance by downregulation of HDAC6 and upregulation of MCAK and PLK1 in prostate cancer cells. (PubMed, Kaohsiung J Med Sci)
Moreover, epidermal growth factor receptor (EGFR) activation induced the upregulation of acetyl-tubulin in docetaxel-resistant PCa cells. These findings demonstrated that the EGFR-mediated upregulated expression of acetyl-tubulin played an important role in docetaxel-resistant PCa.
Journal
|
EGFR (Epidermal growth factor receptor) • PLK1 (Polo Like Kinase 1) • HDAC6 (Histone Deacetylase 6)
|
EGFR expression • PLK1 overexpression
|
docetaxel
8ms
Inhibitory Effect of Fingolimod on Head and Neck Squamous Cell Carcinoma and Its Mechanism: Gene Set Enrichment Analysis. (PubMed, Cell Mol Biol (Noisy-le-grand))
Fingolimod can promote the arrest in G0/G1 of SCC9 cells, and PLK1 is a key targeted gene for the treatment of HNSC. Fingolimod can inhibit cell proliferation caused by PLK1 over-expression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PLK1 (Polo Like Kinase 1)
|
BCL2 expression • PLK1 overexpression
|
fingolimod
9ms
BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines. (PubMed, Pathol Res Pract)
In conclusion, pharmacologic PLK1 inhibition by BI6727 and GSK461364A blocked survival of CCA cells by several mechanisms. Our study provides evidence that BI6727 and GSK461364A could be alternative drugs and have potential implications at the clinical level for CCA therapy.
Preclinical • Journal • PARP Biomarker
|
MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • CCNB1 (Cyclin B1)
|
PLK1 overexpression
|
volasertib (NBL-001) • GSK461364
9ms
Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer. (PubMed, Histopathology)
The prognostic role of PLK1 in BC is molecular subtype-dependent. As PLK1 inhibitors are introduced to clinical trials for several cancer types, our study supports evaluation of the pharmacological inhibition of PLK1 as an attractive therapeutic target in TNBC. However, in luminal BC, PLK1 prognostic role remains controversial.
Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
11ms
Polo-like kinase 1 (PLK1) and AURORA KINASE B modulate Histone Deacetylase 7 (HDAC7) activity in human colorectal cancer cells. (EACR 2023)
HDAC7 can be phosphorylated at SER155, once phosphorylated it can translocate from the cytoplasm to the nucleus...We have employed an original approach, a compound screening, to identify potential modulators of HDAC7. Our data suggest that PLK1 and AURORA B can play a pivotal role in modulate HDAC7 activity and localization, further experiments are needed to better characterized this exciting hypothesis
Epigenetic controller
|
PLK1 (Polo Like Kinase 1) • AURKB (Aurora Kinase B) • HDAC7 (Histone Deacetylase 7)
|
PLK1 overexpression
1year
Tectoridin and PLK1 inhibitor synergistically promote the apoptosis of lung adenocarcinoma cells: Bioinformatic analysis of TCGA and TCMSP. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Tectoridin synergized with PLK1 inhibitor to suppress autophagy and ferroptosis but promoted caspase-3-mediated apoptosis in A549 cells. Our findings highlight a potential drug target and the combination therapy strategy of PLK1 inhibitor and tectoridin for LUAD patients.
Journal • IO biomarker
|
CASP3 (Caspase 3) • ANLN (Anillin Actin Binding Protein) • HMMR (Hyaluronan Mediated Motility Receptor)
|
PLK1 overexpression
1year
Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches. (PubMed, Biomedicines)
To suppress the activation of PLK1, the PLK1 inhibitor BI2536 was administered...Furthermore, the in vivo model proved that cell mitochondrial function and chorionic villi development are both hampered by PLK1 suppression. Our findings revealed that the PLK1/TRAF2/NF-κB axis plays a crucial role in RPL-induced chorionic villi dysfunction by regulating mitochondrial dynamics and apoptosis and might be a potential therapeutic target in the clinic.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TOP2A (DNA topoisomerase 2-alpha) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • MFN2 (Mitofusin 2)
|
PLK1 overexpression
|
BI2536
1year
Overexpression of PLK1 activates IL4/JAK/STAT6 signaling in prostatic tumor-microenvironment (AACR 2023)
Our findings provide clinical and pre-clinical evidence to characterize the role of PLK1 in promoting PCa and novel insights into the regulatory mechanism of PLK1 in the TME. We also provide strong support for the clinical potential of targeting STAT6 for advanced PCa therapy.
JAK3 (Janus Kinase 3) • PLK1 (Polo Like Kinase 1) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • CORIN (Corin, Serine Peptidase)
|
PLK1 overexpression
over1year
3D-QSAR Studies, Molecular Docking, Molecular Dynamic Simulation, and ADMET Proprieties of Novel Pteridinone Derivatives as PLK1 Inhibitors for the Treatment of Prostate Cancer. (PubMed, Life (Basel))
The results of the molecular dynamic MD simulation diagram were obtained to reinforce the previous molecular docking results, which showed that both inhibitors remained stable in the active sites of the PLK1 protein (PDB code: 2RKU) for 50 ns. Finally, a check of the ADME-Tox properties of the two most active molecules showed that molecular N° 28 could represent a good drug candidate for the therapy of prostate cancer diseases.
Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
over1year
Polo-like kinase-1 as a potential prognostic marker of prostate cancer utilizing ORIEN data. (ASCO-GU 2023)
In our study, we did not find RNA-seq PLK1 expression as a potential prognostic marker for prostate cancer. There was no survival difference between low PLK1 vs. high PLK1 expression.
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression • PLK1-H
over1year
Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: A systematic review and meta-analysis. (PubMed, Front Oncol)
Our analysis indicates that high PLK-1 expression is associated with aggressiveness and poor prognosis in malignant neoplasms. Therefore, PLK-1 may be a clinically valuable target for cancer treatment.
Retrospective data • Review
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
over1year
Biodegradable Carbon Dioxide-Derived Non-Viral Gene Vectors for Osteosarcoma Gene Therapy. (PubMed, Adv Healthc Mater)
This study brings a new insight into the development of superior nonviral gene vectors for practical cancer treatment. Based on the results, the resulting nanoparticle-based gene drug formation is considered to have a highly successful chance in further translational nanomedicine applications.
Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
over1year
SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation. (PubMed, Oncogene)
Moreover, we revealed that MYCN directly regulated SMARCE1 transcription through binding to a non-canonical E-box of SMARCE1 promoter, thus enhancing SMARCE1-MYCN cooperativity. These findings establish SMARCE1 is a critical oncogenic factor in neuroblastoma and provide a new potential target for treatment of neuroblastoma with 17q21-ter gain and MYCN amplification.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • PLK1 (Polo Like Kinase 1) • E2F2 (E2F Transcription Factor 2) • ODC1 (Ornithine Decarboxylase 1)
|
MYCN amplification • PLK1 overexpression
over1year
An in-silico Approach: Design, Homology Modeling, Molecular Docking, MM/GBSA Simulations, and ADMET Screening of Novel 1,3,4-oxadiazoles as PLK1inhibitors. (PubMed, Curr Drug Res Rev)
The study showed that the substitution of electron-donating groups at the various position of the aromatic ring, which is bonded at the second position of the substituted 1,3,4-oxadiazole nucleus resulted in compounds with good binding energy and G score compared to the standard drugs, and hence, they can be further developed as potent PLK1 enzyme inhibitors.
Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression • PLK1-H
|
5-fluorouracil • cyclophosphamide
2years
Global expression profiling of CD10 + /CD19 + pre-B lymphoblasts from Hispanic B-ALL patients correlates with comparative TARGET database analysis. (PubMed, Discov Oncol)
A comparative bioinformatics analysis of 15 bone marrow and 10 peripheral blood samples from Hispanic B-ALL patients collected by the TARGET program, corroborated the genes observed, except for PIK3CG. We conclude the Mexican and the Hispanic B-ALL patients studied present common driver alterations and histotype-specific mutations that could facilitate risk stratification and diagnostic accuracy and serve as potential therapeutic targets.
Journal
|
CD19 (CD19 Molecule) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • IL7R (Interleukin 7 Receptor) • PLK1 (Polo Like Kinase 1) • NT5E (5'-Nucleotidase Ecto) • MME (Membrane Metalloendopeptidase) • CDC20 (Cell Division Cycle 20) • TCL1A (TCL1 Family AKT Coactivator A) • RUNX2 (RUNX Family Transcription Factor 2)
|
CD19 expression • PLK1 overexpression • IL7R expression
2years
Plk1 regulates mutant IDH1 enzyme activity and mutant IDH2 ubiquitination in mitosis. (PubMed, Cell Signal)
We conclude that Plk1 regulates mutant IDH1 enzyme activity and mutant IDH2 ubiquitination in mitosis. Based on our results, we suggest that Plk1 can be a therapeutic target in mutant IDH-linked tumours.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • PLK1 (Polo Like Kinase 1) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
IDH1 mutation • IDH2 mutation • PLK1 overexpression
2years
Upregulation of exosomal circPLK1 promotes the development of non-small cell lung cancer through the miR-1294/ high mobility group protein A1 axis. (PubMed, Bioengineered)
Our study suggests that circPLK1 upregulation plays an important role in NSCLC progression by targeting miR-1294/HMGA1 axis. These data provide a theoretical basis for the development of therapeutic strategy targeting exosomal circPLK1 in NSCLC treatment.
Journal
|
HMGA1 (High Mobility Group AT-Hook 1)
|
PLK1 overexpression
over2years
Polo-Like Kinase 1(PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target. (PubMed, Asian Pac J Cancer Prev)
PLK1, although a negative prognostic factor, but is a promising therapeutic target for treating TNBC patients.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • PLK1 (Polo Like Kinase 1)
|
HER-2 negative • PLK1 overexpression • PLK1-H
over2years
Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma. (PubMed, Medicine (Baltimore))
Their expressions in LUAD were associated with tumor stages and relative abundance of tumor infiltrating immune cells, such as B cells, CD4+ T cells, and macrophages. Moreover, cell cycle, DNA replication, homologous recombination, mismatch repair, P53 signaling pathway, and small cell lung cancer signaling were significantly enriched in CDK1 and PLK1 high expression phenotype.CDK1 and PLK1 may be used as potential biomarkers and therapeutic targets for LUAD.
Journal
|
CD4 (CD4 Molecule) • PLK1 (Polo Like Kinase 1) • CDK1 (Cyclin-dependent kinase 1)
|
PLK1 overexpression • PLK1-H
almost3years
[VIRTUAL] Polo-like kinase-1 as a biomarker in resected non-small cell lung cancer (ESMO 2021)
The H-score is a meaningful measure of PLK1 expression in lung tumour tissue. Using the optimal cut point of 5.99 we identified a group of patients with early-stage NSCLC at high risk of relapse. This translated across to OS whereby those with a score of 9.29 and above were at increased risk of death.
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
almost3years
Overexpression of PLK1 relieved the myocardial ischemia-reperfusion injury of rats through inducing the mitophagy and regulating the p-AMPK/FUNDC1 axis. (PubMed, Bioengineered)
However, the inhibition of FUNDC1 abolished the positive effect of PLK1 on H9c2 cells mentioned above. In conclusion, PLK1 alleviated the ischemia reperfusion induced myocardial damage by inducing the mitophagy in a p-AMPK/FUNDC1 signaling dependent pathway.
Preclinical • Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression • AMPK expression
almost3years
Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile. (PubMed, J Cell Mol Med)
Global methylation survival analysis showed that prognostic value of PLK1/2/4 methylation remained the same significant trend between two lung cancer subtypes, whereas prognostic value of PLK3 methylation lacked consistency. Taken together, these results provided instructive insights into a comprehensive evaluation for advanced therapeutic strategy based on epigenetic evidences.
Journal
|
TP53 (Tumor protein P53) • PLK1 (Polo Like Kinase 1) • PLK2 (Polo Like Kinase 2)
|
TP53 mutation • PLK1 overexpression • PLK2 underexpression
over3years
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. (PubMed, Commun Biol)
High Plk1 expression conferred a resistant phenotype of ccRCC to targeted therapeutics such as sunitinib, in vitro, in vivo, and in metastatic ccRCC patients. Importantly, high Plk1 expression was defined in a subpopulation of ccRCC patients that are refractory to current therapies. Hence, we propose a therapeutic paradigm for improving outcomes of ccRCC patients.
Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
|
sunitinib
over3years
Polo like kinase 1 expression in cervical cancer tissues generated from multiple detection methods. (PubMed, PeerJ)
Here, we provided sufficient evidence of PLK1 overexpression in cervical cancer. The overexpression of PLK1 in cervical cancer and the contributory effect of it on clinical progression indicated the hopeful prospect of PLK1 as a biomarker for cervical cancer.
Journal
|
EGFR (Epidermal growth factor receptor)
|
PLK1 overexpression
over3years
Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers. (PubMed, Mutat Res)
On the other hand, we discuss recent evidence that unveils synthetic lethality induction by PLK1 inhibition in BRCA1-deficient cancers cells. This previously unforeseen therapeutic link between PLK1 and BRCA1 is promising because it defines novel therapeutic opportunities for PLK1i not only for breast cancer (i.e. TNBCs with BRCA1 deficiencies), but also for other types of cancers with BRCA1-deficiencies, such as pancreatic and prostate cancers.
Review • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset)
|
PLK1 overexpression